Acumen Research and Consulting, recently published report “Viral Vector & Plasmid DNA Manufacturing Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026”.
LOS ANGELES, May 03, 2019 (GLOBE NEWSWIRE) -- The Global Viral Vector & Plasmid DNA Manufacturing Market size is estimated to grow at CAGR above 21.4 % over the forecast time frame 2019-2026 and reach the market value around USD 1.8 billion by 2026.
Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1335
The market for viral vector & plasmid DNA in the forecast period should be increased by the prevalence and incidence of genetic disorders, infectious diseases, and cancer high unmet needs of rare disorders patients and increasing acceptability of relatively newer treatment alternatives in emerging economies. According to Cancer Research UK, there were 17 million new cases of breast, lung, bowel, prostate cancer in 2018 and four most common cancers in the world, accounting for about 43% of new cases.
In the application of gene therapy, viral vector and plasmid DNA production is used to diagnose patients and treat diseases. High cancer prevalence is projected to boost demand for gene therapy, which will in turn drive market growth. In 2012, cancer is the world's second largest source of morbidity and death, with around 14 million new cases reported in 2012 and 8.8 million deaths reported in 2015 around the world. In addition, WHO stated that by the end of 2030, the number of new cancer cases should increase by about 70 %
In addition, increased research and development activities in the field of the manufacture of viral vectors and plasmid DNA will in the near future boost its demand. In April 2017, for example, Transgene announced plans for the launch of the research collaboration on TG4010 as an advanced non-scrooky, not-small cell lung cancer (NSCLC) treatment for patients with standard chemical therapy (SCT) in combination with Bristol-Myers Squibb's Opdivo (nivolumab).
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/viral-vector-and-plasmid-dna-manufacturing-market
Because of its large use in the manufacture of viral vectors as much as DNA based vaccines, Plasmid DNA sector dominates the global market.
Plasmid DNA is a very attractive part of the global manufacturing market for viral vectors and plasmid DNAs, which is followed by Adeno Associated Viruses (AAV). This is due to the extensive use in the manufacture of various viral vectors of plasmid DNA as the raw material. In addition to the conventional vaccines, various studies have highlighted the benefits of DNA-based vaccines. Due to the various benefits offered by AAV over other vectors, the Adeno-associated Virus segment is likely to enlarge in a significant CAGR over the forecast time period, making them the vector of choice for different clinical studies.
North America dominates the global market
Geographically, five major regions were segmented in the global viral vector & plasmid DNA manufacturing market: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Because of the large patient pool, technological progress, and high acceptance of advanced treatments in the region, North America dominates the global viral vector & plasmid DNA manufacturing industry. During the forecast period, the region is estimated to remain dominant. Additional factors that are expected to boost the viral vector and plasma DNA manufacturing market in the next few years are the increased medical expenditure, availability of approved gene therapy and increased investment.
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
Asia Pacific is projected to expand on the viral vector & plasmid DNA manufacturing market in a remarkably large CAGR because of the growing awareness of viral vector - based products in developing countries and the increased research initiatives in countries such as China and Japan.
Key Players & Strategies
The Viral Vector & Plasmid DNA Manufacturing market is consolidated with large number of manufacturers. Key players expand their product portfolios via mergers, acquisitions and partnerships, which is expected to increase the availability of products and therefore to boost the market.
The key players of the market are CobraBiologics, Novasep, Spark Therapeutics, Inc., FUJIFILM Diosynth Ltd, Cell and Gene Therapy Catapult, Kaneka Eurogentec, Inc. Merck KGaA, Lonza and UniQure N.V. and others.
INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1335
The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1335
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting/
Browse More Press Releases: http://www.amecoresearch.com/press-releases